Prof Andrew Wei presents at ASH 2019, the primary findings from the QUAZAR AML-001 maintenance trial, which evaluated CC-486, an oral formulation of azacitidine as a maintenance therapy in older patients with acute myeloid leukaemia (AML) in first remission following intensive induction chemotherapy.
Watch our interview with Prof Wei here.
Read more about the study here.